Stock listing

NYSE American:OGEN Oragenics Inc. Stock

Home listing (NYSE American) of Oragenics Inc.

Follow Oragenics Inc. into a list and get an email when it puts out news.

Share price · AMEX:OGEN

$0.157 USD -0.032 (-16.9%)

Close on Nov 20, 2026

Past year -82.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.157 – $0.176 USDNov 20, 2026
Volume
323,075 sharesNov 20, 2026
Market cap
$708,377 USDAt the close on Nov 20, 2026 · price × 4.51M shares outstanding
52-week range
$0.157 – $1.110 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$242,246 USDMedian day 22,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Oragenics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:OGEN · Home$0.157 USD-0.032 (-16.9%)323,075$0.176$0.176$0.157$0.189Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:OGEN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.157-0.032-16.9%$0.176$0.176$0.157323,075
$0.189-0.021-10.0%$0.204$0.208$0.181326,785
$0.210+0.012+6.1%$0.183$0.213$0.183665,480
$0.198-0.002-1.0%$0.181$0.201$0.1811,875,147
$0.200-0.150-42.9%$0.210$0.230$0.17016,410,000
$0.350+0.010+2.9%$0.340$0.380$0.34031,772,200
$0.3400.0000.0%$0.350$0.350$0.3402,000
$0.340-0.010-2.9%$0.370$0.370$0.34010,000
$0.3500.0000.0%$0.400$0.400$0.34015,700
$0.3500.0000.0%$0.350$0.350$0.3508,900
$0.350-0.020-5.4%$0.370$0.370$0.34048,300
$0.3700.0000.0%$0.370$0.380$0.3703,700
$0.3700.0000.0%$0.380$0.390$0.3708,400
$0.3700.0000.0%$0.420$0.420$0.37047,800
$0.3700.0000.0%$0.370$0.390$0.3709,200
$0.370-0.010-2.6%$0.380$0.380$0.3706,300
$0.380+0.010+2.7%$0.380$0.400$0.37013,800
$0.370-0.030-7.5%$0.400$0.400$0.35062,400
$0.400-0.020-4.8%$0.420$0.420$0.40017,300
$0.420+0.010+2.4%$0.410$0.420$0.4009,400
$0.4100.0000.0%$0.410$0.410$0.40020,400
$0.410-0.020-4.7%$0.440$0.440$0.4105,300
$0.430+0.010+2.4%$0.440$0.450$0.41014,800
$0.420-0.010-2.3%$0.440$0.450$0.42036,000
$0.430-0.010-2.3%$0.450$0.450$0.43032,700
$0.4400.0000.0%$0.430$0.460$0.43011,600
$0.440-0.010-2.2%$0.450$0.450$0.43016,900
$0.4500.0000.0%$0.450$0.450$0.44016,300
$0.450-0.010-2.2%$0.460$0.460$0.45017,200
$0.4600.0000.0%$0.470$0.480$0.45028,200
$0.460-0.040-8.0%$0.500$0.500$0.46045,800
$0.500+0.010+2.0%$0.500$0.500$0.49011,600
$0.4900.0000.0%$0.490$0.490$0.48012,300
$0.4900.0000.0%$0.480$0.500$0.48042,300
$0.490+0.010+2.1%$0.480$0.500$0.48015,400
$0.480-0.010-2.0%$0.490$0.520$0.48032,400
$0.490+0.010+2.1%$0.480$0.500$0.47014,400
$0.480+0.010+2.1%$0.490$0.490$0.46042,000
$0.470-0.020-4.1%$0.510$0.510$0.46033,300
$0.490-0.010-2.0%$0.520$0.520$0.48011,800
$0.500+0.010+2.0%$0.490$0.500$0.49017,400
$0.490-0.030-5.8%$0.520$0.530$0.49040,000
$0.5200.0000.0%$0.520$0.530$0.50025,300
$0.520+0.040+8.3%$0.480$0.520$0.48037,900
$0.480-0.040-7.7%$0.500$0.520$0.48043,000
$0.520+0.020+4.0%$0.500$0.520$0.49048,900
$0.500+0.010+2.0%$0.500$0.520$0.48054,500
$0.490-0.010-2.0%$0.490$0.500$0.48025,200
$0.500+0.020+4.2%$0.480$0.500$0.48023,500
$0.480-0.020-4.0%$0.500$0.500$0.48066,900
$0.500-0.020-3.8%$0.510$0.510$0.5009,200
$0.5200.0000.0%$0.520$0.520$0.5104,700
$0.520+0.010+2.0%$0.510$0.520$0.51012,600
$0.510+0.010+2.0%$0.500$0.520$0.5008,300
$0.500-0.010-2.0%$0.510$0.520$0.50022,900
$0.510+0.010+2.0%$0.510$0.530$0.50025,300
$0.500-0.010-2.0%$0.500$0.520$0.50016,100
$0.510-0.010-1.9%$0.520$0.530$0.490101,200
$0.520-0.010-1.9%$0.530$0.530$0.52073,800
$0.5300.0000.0%$0.530$0.540$0.51029,600
$0.530+0.010+1.9%$0.540$0.540$0.5207,200
$0.5200.0000.0%$0.510$0.530$0.51012,900
$0.520-0.010-1.9%$0.520$0.530$0.51030,400
$0.530-0.010-1.9%$0.530$0.540$0.52056,400
$0.540+0.010+1.9%$0.550$0.550$0.53016,000

Splits

4 splits since 2010 · AMEX:OGEN · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
1-for-60Consolidation
1-for-10Consolidation
1-for-20Consolidation
Ticker
NYSE American:OGEN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Oragenics Inc. news

Oragenics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 30 in all · newest Nov 12, 2026 · oldest 2025
Decks
28 decks · latest Sep 16, 2026

Where Oragenics Inc. is listed

ListingExchangeCountryCurrency
NYSE American:OGEN · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:OGENBOATSUnited StatesUSD
gettex:UAV0gettexGermanyEUR
LSE:0A64LSEUnited KingdomUSD
Munich:UAV0MunichGermanyEUR

Valuation

Price/book 0.7× against a median of 0.2×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$1.12M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.4×
Beta vs S&P 500
1.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Oragenics Inc. · AMEX:OGENUS$708,377−US$1.12Mn/an/an/a0.7×n/a0.4×1.47
Valion Bio, Inc. · NASDAQ:VBIOUS$1.04MUS$16.34Mn/a42.8×n/a0.2×n/a4.1×1.11
GeoVax Labs, Inc. · NASDAQ:GOVXUS$985,460−US$915,033n/an/an/a0.9×n/a0.2×1.47
Biodexa Pharmaceuticals plc · NASDAQ:BDRXUS$982,950−US$3.22Mn/an/an/a0.1×n/a0.0×1.01
Gabather AB · OMXSTO:GABAUS$922,076US$560,663n/an/an/a6.4×n/a0.0×n/a
ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2US$794,844−US$2.43Mn/a−6.5×n/a0.2×−935.9%0.0×n/a
Silexion Therapeutics Corp · NASDAQ:SLXNUS$790,001−US$3.60Mn/an/an/a0.3×n/a0.1×2.77
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Median of the othersUS$792,423−US$1.20M0.1×−0.1×0.2×−558.9%0.0×1.23

Forecasts

1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
2.00 USD · Analysts' mean
EPS, year to Dec 2025
-0.76 · 1 analyst

Team and board

Officers

OfficerRole
Janet HuffmanChief Executive Officer & Chief Financial Officer
Frederick W. TellingExecutive Chairman
James P. KellyChief Medical Officer
William Frank PeacockChief Clinical Officer

Board

DirectorRole
Charles L. PopeChairman of the Board
Frederick W. TellingExecutive Chairman
Alan DuntonDirector
John GandolfoDirector
Natasha GiordanoBoard Member
Robert KoskiDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026−41.2%
Q2 2026Aug 13, 2026−1.9%
Q1 2026May 8, 2026−8.2%
Q3 2025Nov 7, 20250.0%
Q2 2025Aug 8, 2025−10.0%
Q1 2025May 9, 20250.0%
Q4 2024Mar 27, 2025 · After close−4.3%
Q3 2024Nov 7, 2024 · After close+21.9%
Q2 2024Aug 9, 2024 · After close+48.6%
Q1 2024May 15, 2024 · After close0.0%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 29, 2024 · After close−0.7%
Q3 2023Nov 9, 2023 · After close−4.0%
Q2 2023Aug 11, 2023 · After close+0.6%
Q1 2023May 12, 2023 · After close−0.3%
Q4 2022Mar 27, 2023 · After close+12.6%
Q3 2022Nov 14, 2022 · After close+4.8%
Q2 2022Aug 9, 2022 · After close0.0%
Q1 2022May 13, 2022 · After close−3.7%
Q4 2021Mar 24, 2022 · After close−10.5%
Quarter to Sep 30, 2021Nov 15, 2021 · After close−3.3%

Open Events

Decks

DeckKindSlidesDate
IPAC-RS Successful Studies Case (September 2026)Conference21 slidesSep 16, 2026
Investor Presentation (May 2026)Investor deck15 slidesMay 2026
Investor Presentation (January 2026)Investor deck17 slidesJan 20, 2026
Corporate Update (May 2025)Corporate update28 slidesMay 20, 2025
Investor Presentation (October 2024)Investor deck16 slidesOct 16, 2024
Investor Presentation (November 2023)Investor deck8 slidesNov 20, 2023
Investor Presentation (April 2023)Investor deck14 slidesApr 3, 2023
Investor Presentation (October 2022)Investor deck14 slidesOct 3, 2022
Investor Presentation (April 2022)Investor deck11 slidesApr 19, 2022
Investor Presentation (November 2021)Investor deck21 slidesNov 12, 2021
All 28 decks
DeckKindSlidesDate
Investor Presentation (March 2021)Investor deck30 slidesMar 9, 2021
Investor Presentation (November 2020)Investor deck29 slidesNov 10, 2020
Investor Presentation (August 2020)Investor deck27 slidesAug 18, 2020
Investor Presentation (May 2020)Investor deck27 slidesMay 8, 2020
Investor Presentation (March 2020)Investor deck24 slidesMar 13, 2020
Investor Presentation (December 2019)Investor deck24 slidesDec 4, 2019
Investor Presentation (October 2019)Investor deck22 slidesOct 22, 2019
Investor Presentation (September 2019)Investor deck24 slidesSep 6, 2019
Investor Presentation (December 2018)Investor deck22 slidesDec 3, 2018
Investor Presentation (October 2018)Investor deck22 slidesOct 1, 2018
Investor Presentation (September 2018)Investor deck19 slidesSep 25, 2018
Investor Presentation (August 2018)Investor deck28 slidesAug 15, 2018
IPO Roadshow (July 2018)IPO roadshow30 slidesJul 5, 2018
Investor Presentation (April 2017)Investor deck31 slidesApr 18, 2017
Investor Presentation (January 2017)Investor deck28 slidesJan 31, 2017
Investor Presentation (January 2014)Investor deck26 slidesJan 16, 2014
Investor Presentation (October 2013)Investor deck20 slidesOct 18, 2013
Investor Presentation (January 2009)Investor deck32 slidesJan 15, 2009

Open Decks

Financings

RaiseDate
Public offering of series H Convertible Preferred Stock and Warrants
Closed: US$16.5M raised · US$25 a share · 1 warrant at US$25 for 60 months · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Use of proceeds: Clinical development of ONP-002, other R&D, repay a $3 million bridge note, working capital and general corporate purposes
Jul 2, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0037.7K131.5K87.0K00000
Cost of revenue4.11M15.5M44.7K41.2K22.1M62.6K30.1K00
Gross profit-4.11M-27.4K86.9K45.8K-22.1M-62.6K-30.1K00
Research and development2.39M4.11M15.5M10.1M10.6M22.1M12.1M5.97M3.54M4.75M
Selling, general and administrative6.97M6.44M5.45M4.48M5.27M4.53M3.76M4.02M3.18M3.79M
Operating income-9.36M-10.6M-20.9M-14.4M-15.8M-26.6M-15.9M-9.99M-6.72M-8.54M
Depreciation and amortization771.4M027.4K44.7K41.2K51.7K62.6K30.1K65.8K75.0K
EBITDA762.1M-10.6M-20.9M-14.4M-15.7M-26.6M-15.8M-9.96M-6.65M-8.47M
Interest expense785.9K29.8K30.6K15.1K15.8K10.7K7.30K5.79K216.3K4.12K
Income before tax-9.98M-10.6M-20.7M-14.3M-15.7M-26.4M-15.6M-9.91M-6.73M-8.50M
Income tax-136.9K-1-127.0K16.4K12.5K7.76K000
Net income-9.84M-10.6M-20.7M-14.3M-15.7M-26.4M-15.6M-9.91M-6.73M-7.01M
Earnings per share, basic-4.56-47.88-9.18-7.11-8.09-0.47-0.37-0.87-1.37-1.57
Earnings per share, diluted-4.56-47.88-9.18-7.11-0.14-0.47-0.37-0.87-1.37-1.57

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.40M864.8K3.48M11.4M27.3M17.6M18.3M20.2M6.17M4.08M
Short-term investments4.00M017.9K00
Receivables53.1K6.99K6.99K0
Inventory00
Current assets10.1M1.47M3.87M14.3M27.7M18.0M18.8M21.9M7.19M4.22M
Property, plant and equipment0121.1K45.7K42.7K92.0K116.3K21.7K87.5K
Goodwill00
Total assets10.1M1.47M4.97M14.8M28.2M18.7M19.8M22.0M7.21M4.31M
Accounts payable1.56M1.14M1.24M246.7K855.0K330.4K1.21M828.7K618.4K461.3K
Current liabilities1.79M1.68M1.80M1.60M1.45M1.34M1.85M1.17M898.5K1.34M
Long-term debt00
Total debt227.3K328.5K322.5K624.5K797.2K898.9K979.6K124.2K80.5K66.4K
Total liabilities1.79M1.68M1.80M1.75M1.74M1.84M2.52M1.17M898.5K1.34M
Shareholders' equity8.28M-211.9K3.17M13.0M26.5M16.8M17.2M20.9M6.32M2.97M
Shares outstanding4.27M419.0K3.08M2.02M2.00M91.8M46.1M29.4M4.93M4.91M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-9.25M-8.60M-7.29M-15.2M-13.5M-17.0M-13.0M-9.08M-6.36M-7.08M
Capital spending-30-1.00M-127.5K-43.9K-43.9K-25.2K-124.7K-124.7K-27.2K
Free cash flow-9.25M-8.60M-8.29M-15.4M-13.5M-17.0M-13.0M-9.20M-6.36M-7.10M
Cash from investing-936.3K-115.5K-43.9K-43.9K-25.2K-124.7K-124.7K1.68M
Cash from financing16.8M5.98M283.9K-494.9K23.1M16.3M11.1M23.2M8.45M4.45M
Dividends paid-1.12M-1.12M-661.5K-413.2K-58.7K00
Share buybacks-5.64M-5.64M661.5K252.9K58.7K6.18M2.64M
Change in cash7.53M-2.62M-7.94M-15.8M9.63M-628.4K-1.94M14.0M2.09M-948.6K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportSep 16, 2026Current reportSEC
8-K · Current reportAug 28, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJul 6, 2026Material contractSEC
DEFA14A · Additional proxy materialMay 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 20, 2026Meeting noticeSEC
8-K · Current reportMay 19, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementMay 8, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026Current reportSEC
8-K · Current reportApr 13, 2026Current reportSEC
8-K · Current reportMar 31, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMar 23, 2026Other filingsSEC
CORRESP · Letter to the SECMar 19, 2026Other filingsSEC
S-3/A · Registration statement, amendedMar 19, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 11, 2026Current reportSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
S-3 · Registration statementJan 22, 2026Offer documentSEC
8-K · Current reportJan 22, 2026Material contractSEC
4/A · Change in ownership, amendedJan 22, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
8-K · Current reportJan 20, 2026Current reportSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
8-K · Current reportNov 12, 2025Current reportSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
8-K · Current reportOct 21, 2025Material contractSEC
8-K · Current reportSep 2, 2025Management or board changeSEC
3 · Initial statement of ownershipSep 2, 2025Insider tradeSEC
S-8 · Registration statement for employee plansAug 26, 2025Offer documentSEC
8-K · Current reportAug 11, 2025Current reportSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportJul 2, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeJul 2, 2025Big-stake noticeSEC
424B5 · ProspectusJul 2, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 1, 2025Other filingsSEC
S-1/A · Registration statement, amendedJun 30, 2025Offer documentSEC
CORRESP · Letter to the SECJun 26, 2025Other filingsSEC
CORRESP · Letter to the SECJun 26, 2025Other filingsSEC
CORRESP · Letter to the SECJun 23, 2025Other filingsSEC
S-1 · Registration statementJun 23, 2025Offer documentSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
UPLOAD · Letter from the SECJun 17, 2025Other filingsSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 16, 2025Insider tradeSEC
144 · Notice of proposed saleJun 13, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftJun 2, 2025Other filingsSEC
DRS · Draft registration statementJun 2, 2025Offer documentSEC
8-K · Current reportMay 28, 2025Current reportSEC
8-K · Current reportMay 20, 2025Current reportSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 2, 2025Material contractSEC
UPLOAD · Letter from the SECApr 28, 2025Other filingsSEC
DEFA14A · Additional proxy materialApr 11, 2025Meeting noticeSEC
CORRESP · Letter to the SECApr 11, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 10, 2025Other filingsSEC
8-K · Current reportApr 9, 2025Current reportSEC
DEF 14A · Proxy statementApr 1, 2025Meeting noticeSEC
8-K · Current reportMar 27, 2025Current reportSEC
PRE 14A · Preliminary proxy statementMar 19, 2025Meeting noticeSEC
10-K · Annual reportMar 14, 2025Annual reportSEC
8-K · Current reportMar 6, 2025Current reportSEC
8-K · Current reportFeb 18, 2025Current reportSEC
8-K · Current reportFeb 5, 2025Current reportSEC
RW · Request to withdraw a registrationFeb 4, 2025Other filingsSEC
8-K · Current reportJan 21, 2025Current reportSEC
8-K · Current reportJan 17, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveJan 17, 2025Other filingsSEC
CORRESP · Letter to the SECJan 14, 2025Other filingsSEC
S-1/A · Registration statement, amendedJan 8, 2025Offer documentSEC
S-1/A · Registration statement, amendedDec 31, 2024Offer documentSEC
CORRESP · Letter to the SECDec 31, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 30, 2024Other filingsSEC
S-1 · Registration statementDec 19, 2024Offer documentSEC
8-K · Current reportDec 16, 2024Management or board changeSEC
S-8 · Registration statement for employee plansDec 16, 2024Offer documentSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
144 · Notice of proposed saleDec 6, 2024Other filingsSEC
144 · Notice of proposed saleDec 6, 2024Other filingsSEC
8-K · Current reportNov 29, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialOct 31, 2024Meeting noticeSEC
DEF 14A · Proxy statementOct 31, 2024Meeting noticeSEC
8-K · Current reportOct 18, 2024Current reportSEC
8-K · Current reportOct 16, 2024Current reportSEC
8-K · Current reportOct 11, 2024Material contractSEC
424B5 · ProspectusOct 11, 2024Offer documentSEC
8-K · Current reportOct 9, 2024Current reportSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
8-K · Current reportSep 20, 2024Management or board changeSEC
SC 13G · Big-stake noticeSep 11, 2024Big-stake noticeSEC
8-K · Current reportSep 5, 2024Material contractSEC
424B5 · ProspectusSep 5, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 4, 2024Other filingsSEC
CORRESP · Letter to the SECSep 3, 2024Other filingsSEC
CORRESP · Letter to the SECSep 3, 2024Other filingsSEC
S-1/A · Registration statement, amendedSep 3, 2024Offer documentSEC
UPLOAD · Letter from the SECAug 23, 2024Other filingsSEC
8-K · Current reportAug 21, 2024Current reportSEC
S-1 · Registration statementAug 16, 2024Offer documentSEC
8-K · Current reportAug 16, 2024Current reportSEC
8-K · Current reportAug 14, 2024Current reportSEC
8-K · Current reportAug 12, 2024Current reportSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024Current reportSEC
8-K · Current reportJul 22, 2024Current reportSEC
8-K · Current reportJul 10, 2024Current reportSEC
8-K · Current reportJun 26, 2024Material contractSEC
424B5 · ProspectusJun 25, 2024Offer documentSEC
424B5 · ProspectusJun 24, 2024Offer documentSEC
8-K · Current reportJun 20, 2024Current reportSEC
8-K · Current reportMay 23, 2024Current reportSEC
8-K · Current reportMay 22, 2024Current reportSEC
8-K · Current reportMay 17, 2024Current reportSEC
8-K · Current reportMay 16, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024Current reportSEC
8-K · Current reportApr 19, 2024Current reportSEC
8-K · Current reportApr 15, 2024Current reportSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
8-K · Current reportMar 18, 2024Current reportSEC
SC 13G · Big-stake noticeMar 6, 2024Big-stake noticeSEC
8-K · Current reportMar 1, 2024Material contractSEC
424B5 · ProspectusFeb 29, 2024Offer documentSEC
8-K · Current reportFeb 28, 2024Current reportSEC
8-K · Current reportFeb 27, 2024Current reportSEC
FWP · Free writing prospectusFeb 27, 2024Offer documentSEC
424B5 · ProspectusFeb 27, 2024Offer documentSEC
SC 13D · Big-stake noticeFeb 12, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024Management or board changeSEC
8-K · Current reportFeb 7, 2024Current reportSEC
8-K · Current reportFeb 5, 2024Current reportSEC
8-K · Current reportJan 23, 2024Current reportSEC
5 · Annual statement of ownershipJan 22, 2024Insider tradeSEC
8-K · Current reportJan 16, 2024Current reportSEC
FWP · Free writing prospectusJan 16, 2024Offer documentSEC
424B5 · ProspectusJan 16, 2024Offer documentSEC
S-8 · Registration statement for employee plansJan 10, 2024Offer documentSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
8-K · Current reportJan 2, 2024Current reportSEC
8-K · Current reportDec 29, 2023Acquisition or disposalSEC
8-K · Current reportDec 15, 2023Management or board changeSEC
8-K · Current reportDec 8, 2023Current reportSEC
4 · Change in ownershipDec 1, 2023Insider tradeSEC
144 · Notice of proposed saleNov 30, 2023Other filingsSEC
8-K · Current reportNov 20, 2023Current reportSEC
DEFA14A · Additional proxy materialNov 16, 2023Meeting noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023Current reportSEC
DEFA14A · Additional proxy materialNov 2, 2023Meeting noticeSEC
DEFA14A · Additional proxy materialOct 30, 2023Meeting noticeSEC
DEF 14A · Proxy statementOct 30, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 6, 2023Meeting noticeSEC
4 · Change in ownershipOct 6, 2023Insider tradeSEC
4 · Change in ownershipOct 6, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 6, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 6, 2023Insider tradeSEC
8-K · Current reportOct 5, 2023Management or board changeSEC
8-K · Current reportOct 5, 2023Material contractSEC
8-K · Current reportSep 29, 2023Current reportSEC
8-K · Current reportSep 15, 2023Current reportSEC
8-K · Current reportAug 18, 2023Current reportSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
8-K · Current reportAug 10, 2023Management or board changeSEC
DAug 7, 2023Other filingsSEC
8-K · Current reportAug 7, 2023Material contractSEC
8-K · Current reportJun 5, 2023Current reportSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
10-K · Annual reportApr 17, 2023Annual reportSEC
10-Q/A · Quarterly report, amendedApr 14, 2023Quarterly reportSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Oragenics Inc.’s releases · as of Nov 11, 2026

Common shares
4,511,957
Fully diluted
5,171,957

Fully diluted

LineSharesAs of
Common shares4,511,957Nov 11, 2026
Warrants660,000Jul 2, 2025

Warrants and options

Lot
Warrants · US$25.00 · expire about Jul 2030

Share count over time

CountShares
Nov 11, 20264,511,957

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
HUB Investment Partners, LLC40,0000.89%US$19,672NewNov 3, 2026
Geode Capital23,6850.52%US$11,647No changeNov 6, 2026
25 LLC23,1600.51%US$11,390No changeOct 13, 2026
Citadel13,5140.30%US$6,646NewNov 16, 2026
Tower Research Capital LLC (TRC)4,5470.10%US$2,236−1Nov 16, 2026
St. Johns Investment Management Company, LLC1,9240.04%US$946No changeOct 30, 2026
Citigroup Inc1,5190.03%US$747NewNov 4, 2026
BlackRock7030.02%US$346No changeNov 13, 2026
Fidelity103<0.01%US$51NewNov 10, 2026
Harbour Investments, Inc.34<0.01%US$17No changeNov 9, 2026
All 17 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
SBI Securities Co., Ltd.18<0.01%US$9−5Oct 21, 2026
Adkins Seale Capital Management LLC3<0.01%US$1No changeOct 27, 2026
RBC2<0.01%No changeNov 16, 2026
Strategic Wealth Partners, Ltd.1<0.01%No changeNov 13, 2026
Farther Finance Advisors, LLC1<0.01%No changeOct 8, 2026
Keating Financial Advisory Services, Inc.1<0.01%No changeNov 12, 2026
Bogart Wealth, LLC1<0.01%No changeNov 10, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Extended Market Index Fund63,3791.4%US$38,395+24,016May 31, 2026

Big stakes

HolderStakeSharesDate
Sabby Management, LLC9.90%413KDec 31, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John P. Gandolfo
Other companies: electroCore, Inc. (Audit Committee Member, Compensation Committee Member · Since at least Apr 2, 2020); Odyssey Health Inc. (Director · Oct 23, 2019 – Jan 12, 2023 · Past); Hyperion DeFi, Inc. (Chief Financial Officer · Jan 24, 2018 – Feb 12, 2024 · Past); Xtant Medical Holdings, Inc. (CFO · Mar 4, 2011 – Sep 4, 2014 · Past); Power Medical Interventions Inc (Chief Financial Officer · Oct 25, 2007 – Apr 9, 2008 · Past); Bioject Medical Technologies Inc (Director · Mar 24, 2006 – Aug 11, 2006 · Past)
Director · Since at least Oct 4, 2023
Alan W. Dunton
Other companies: CorMedix Inc. (Director · Since at least Mar 1, 2019); Palatin Technologies, Inc. (Director · Since at least Jun 22, 2011); Adams Respiratory Therapeutics Inc (Director · Nov 8, 2006 – Jan 29, 2008 · Past); Gyre Therapeutics, Inc. (Director · Oct 18, 2006 – Aug 14, 2015 · Past); MediciNova, Inc. (Director · May 11, 2006 – Jun 11, 2010 · Past)
Director · Since at least Apr 1, 2011
John N Bonfiglio
Other companies: Qrons Inc (Chief Operating Officer · Jul 1, 2019 – Jul 1, 2019 · Past); Genprex, Inc. (Director · Feb 12, 2019 – Feb 12, 2019 · Past); Marker Therapeutics, Inc. (President and COO, Director · Jul 23, 2015 – Mar 9, 2017 · Past); Harrow, Inc. (President and CEO, Director · Oct 20, 2010 – Oct 20, 2010 · Past)
President and CEO, Director · May 25, 2011 – Aug 13, 2014 · Past
Charles L. Pope
Other companies: Scienture Holdings, Inc. (Director · Aug 11, 2014 – Sep 1, 2022 · Past); Innovaro Inc. (Director · Mar 3, 2010 – May 2, 2012 · Past); Inuvo, Inc. (Director · Sep 9, 2008 – Jun 30, 2018 · Past)
Chairman of the Board · Since at least Jun 4, 2010
Kimberly M Murphy
Other companies: Onconetix, Inc. (Director · Feb 17, 2022 – May 4, 2022 · Past); Clarus Therapeutics Holdings Inc (Director · Dec 12, 2021 – Jun 7, 2022 · Past); Blue Water Acquisition Corp (Director · Dec 14, 2020 – Dec 14, 2020 · Past)
Director · May 1, 2020 – Sep 19, 2024 · Past
Bruce A Cassidy Sr
Other companies: Interlink Plus Inc (Director · Nov 20, 2019 – Nov 20, 2019 · Past); Ohio Legacy Corp (Director · Feb 19, 2010 – Feb 19, 2010 · Past)
Director · Oct 4, 2023 – Sep 19, 2024 · Past
Natasha Giordano
Other companies: Matinas BioPharma Holdings, Inc. (Director · Nov 1, 2021 – Nov 1, 2023 · Past); PLx Pharma Inc (Chief Executive Officer, Director · Nov 18, 2020 – Mar 15, 2022 · Past)
Director · Since at least Sep 1, 2025
Alan Joslyn
Other companies: Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jun 16, 2018 · Past)
CEO and President, Director · Jun 6, 2016 – Feb 18, 2021 · Past
Frederick W. Telling
Other companies: CTi Biopharma Corp (Director · Nov 11, 2011 – Sep 18, 2018 · Past)
Executive Chairman · Since at least Nov 14, 2011
Janet Huffman
Other companies: Scienture Holdings, Inc. (CFO, PAO, PFO · Apr 2, 2022 – Dec 13, 2022 · Past)
Chief Executive Officer & Chief Financial Officer · Since at least Mar 7, 2023
All 27 people
PersonSeat
J. Michael Redmond
Other companies: Odyssey Health Inc. (Chairman of the Board · Since at least Nov 28, 2018)
President · Dec 28, 2023 – Sep 19, 2024 · Past
Robert Koski
Other companies: Helios Technologies, Inc. (Director · Jun 30, 2016 – Jul 12, 2016 · Past)
Director · Since at least Sep 17, 2013
Brian AndersonDirector · Oct 3, 2005 – Oct 3, 2005 · Past
Brian John BohunickyCFO, Secretary and Treasurer · Jun 29, 2009 – Nov 14, 2011 · Past
David Brian HirschPresident and CEO, Director · Jun 27, 2008 – Dec 1, 2009 · Past
Derek HenneckeDirector · Jan 2, 2008 – May 9, 2008 · Past
Dorothy Jean DelfinoCFO AND SECRETARY · Jun 1, 2007 – May 21, 2008 · Past
George T HawesDirector · Mar 6, 2006 – Feb 29, 2008 · Past
James P. KellyChief Medical Officer · Since at least May 19, 2026
Jeffrey D HillmanChief Scientific Officer, Director · Mar 6, 2006 – Oct 12, 2011 · Past
John SpencerChief Financial Officer · Since at least Jul 1, 2026
Marc K SiegelDirector · Apr 28, 2008 – May 9, 2008 · Past
Michael O'Keefe SullivanChief Financial Officer · Feb 5, 2020 – Jul 29, 2022 · Past
Richard T WelchDirector · Jan 2, 2008 – May 9, 2008 · Past
Ronald P EvensCEO & President, Director · Jun 15, 2007 – Jan 28, 2008 · Past
Stanley Bruce SteinPresident & CEO, Director · Jan 21, 2008 – Apr 8, 2008 · Past
William Frank PeacockChief Clinical Officer · Since at least May 19, 2026

Open People

Log in to ask 6ix AI your own questions about Oragenics Inc.